Pasar al contenido principal

INTEGRACION DE SEÑALES DEL TCR Y EL COMPLEMENTO POR LOS LINFOCITOS

RTI2018-095673-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Inherited human ezrin deficiency impairs adaptive immunity

  • García-Solís, Blanca et al.
  • Rebeca Pérez de Diego
  • Martínez Martínez, Laura María
  • Recio Hoyas, María José
  • Fernández Arquero, Miguel
  • Sánchez Ramón, Silvia María
Background Inborn errors of immunity (IEI) are a group of monogenic diseases that confer susceptibility to infection, autoimmunity, and cancer. Despite the life-threatening consequences of some IEI, their genetic cause remains unknown in many patients. Objective We investigated a patient with an IEI of unknown genetic etiology. Methods Whole-exome sequencing identified a homozygous missense mutation of the gene encoding ezrin (EZR), substituting a threonine for an alanine at position 129. Results Ezrin is one of the subunits of the ezrin, radixin, and moesin (ERM) complex. The ERM complex links the plasma membrane to the cytoskeleton and is crucial for the assembly of an efficient immune response. The A129T mutation abolishes basal phosphorylation and decreases calcium signaling, leading to complete loss of function. Consistent with the pleiotropic function of ezrin in myriad immune cells, multidimensional immunophenotyping by mass and flow cytometry revealed that in addition to hypogammaglobulinemia, the patient had low frequencies of switched memory B cells, CD4+ and CD8+ T cells, MAIT, γδ T cells, and centralnaive CD4+ cells. Conclusions Autosomal-recessive human ezrin deficiency is a newly recognized genetic cause of B-cell deficiency affecting cellular and humoral immunity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells

  • Molina Hoyo, Ester
  • García-Gutiérrez, Lucía
  • Junco, Vanessa
  • Perez-Olivares, Mercedes
  • Yébenes, Virginia G. de
  • Blanco, Rosa
  • Quevedo, Laura
  • Acosta, Juan C.
  • Marín, Ana V.
  • Ulgiati, Daniela
  • Merino, Ramón
  • Delgado, M. Dolores
  • Varela, Ignacio
  • Regueiro, José R.
  • Moreno de Alborán, Ignacio
  • Ramiro, Almudena R.
  • León, Javier
MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. While transcriptomic studies reveal more than 1000 genes regulated by MYC, a much smaller fraction of genes is directly transactivated by MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving MYC oncogene. Most endemic BL and a fraction of sporadic BL are associated with Epstein–Barr virus (EBV) infection. The currently accepted mechanism is that EBV is the BL-causing agent inducing MYC translocation. Herein we show that the EBV receptor, CR2 (also called CD21), is a direct MYC target gene. This is based on several pieces of evidence: MYC induces CR2 expression in both proliferating and arrested cells and in the absence of protein synthesis, binds the CR2 promoter and transactivates CR2 in an E-box-dependent manner. Moreover, using mice with conditional MYC ablation we show that MYC induces CR2 in primary B cells. Importantly, modulation of MYC levels directly correlates with EBV’s ability of infection in BL cells. Altogether, in contrast to the widely accepted hypothesis for the correlation between EBV and BL, we propose an alternative hypothesis in which MYC dysregulation could be the first event leading to the subsequent EBV infection., The work was supported by grants PID2020-115903GB-100 to JL and MDD, RTI2018-095673-B-I00 to JRR, PID2019-107551RB-I00 to VG-Y, PID2020-119567RB-I00 to RM, PID2020-117539GB-I00 to IV and PID2019-106773RB-I00 to ARR, all funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union, and by La Caixa HR17-0244 grant to AR. LQ and VJ were recipients of F.P.U. program and Universidad de Cantabria fellowships, respectively. LG-G was a fellow of the Maria Zambrano program, Spanish Government.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary material to: Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
Supplementary methods, tables (1-4) and figures legends (1-10)., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nonsense CD247 mutations show dominant-negative features in T-cell receptor expression and function

  • Briones, Alejandro C
  • Megino, Rebeca F
  • Marin, Ana V
  • Chacón-Arguedas, Daniel
  • García-Martinez, Elena
  • Balastegui-Martín, Héctor
  • Reyburn, Hugh T
  • Henrickson, Sarah E
  • Rodríguez-Sainz, Carmen
  • Seoane-Reula, Elena
  • Sanchez-Mateos, Paloma
  • Cardenas, Paula P
  • Regueiro, Jose R
The invariant TCR ζ/CD247 homodimer is crucial for TCR/CD3 expression and signaling through its 3 immunoreceptor tyrosine-based activation motifs (ITAMs). Homozygous null mutations in CD247 lead to immunodeficiency, while carriers exhibit 50% reduced surface CD3. It is unclear whether carriers of other CD247 variants show dominant-negative effects., This work was supported by grants from the Ministerio de Economía y Competitividad (MINECO PID2021-125501OB-I00 and RTI2018-095673-B-I00) and Asociación Española Contra el Cancer (AECC PROYE20084REGU). A.C.B. was supported by Complutense University scholarship (CT27/16 and CT31/21). R.F.M. and D.C.A. were supported by the Spanish Ministry of Science, Innovation and Universities (FPU19/03136 and PRE2019-088150). P.P.C. was supported by Juan de la Cierva-Incorporacion fellowship (IJCI-2014-19262)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inherited human ezrin deficiency impairs adaptive immunity

  • García Solis, Blanca|||0000-0002-3718-2560
  • Van Den Rym, Ana
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Franco Leyva, Teresa|||0000-0002-0250-0274
  • Pérez-Caraballo, Jareb J.
  • Markle, Janet
  • Cubillos-Zapata, Carolina
  • Marín, Ana V.
  • Recio, María J.
  • Regueiro, José R.|||0000-0001-8442-7762
  • Navarro-Zapata, Alfonso
  • Mestre-Durín, Carmen
  • Ferreras, Cristina
  • Cotázar, Carla Martín
  • Mena, Roció
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • López-Lera, Alberto|||0000-0002-9596-6910
  • Arquero, Miguel Fernández
  • Pérez Martínez, Antonio|||0000-0002-6436-9195
  • López-Collazo, Eduardo
  • Sánchez Ramón, Silvia|||0000-0001-9585-6167
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Martínez-Barricarte, Rubén
  • Calle Martín, Óscar de la|||0000-0001-9717-053X
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
Inborn errors of immunity (IEI) are a group of monogenic diseases that confer susceptibility to infection, autoimmunity, and cancer. Despite the life-threatening consequences of some IEI, their genetic cause remains unknown in many patients. Objective: We investigated a patient with an IEI of unknown genetic etiology. Whole-exome sequencing identified a homozygous missense mutation of the gene encoding ezrin (EZR), substituting a threonine for an alanine at position 129. Ezrin is one of the subunits of the ezrin, radixin, and moesin (ERM) complex. The ERM complex links the plasma membrane to the cytoskeleton and is crucial for the assembly of an efficient immune response. The A129T mutation abolishes basal phosphorylation and decreases calcium signaling, leading to complete loss of function. Consistent with the pleiotropic function of ezrin in myriad immune cells, multidimensional immunophenotyping by mass and flow cytometry revealed that in addition to hypogammaglobulinemia, the patient had low frequencies of switched memory B cells, CD4 + and CD8 + T cells, MAIT, γδ T cells, and central naive CD4 + cells. Autosomal-recessive human ezrin deficiency is a newly recognized genetic cause of B-cell deficiency affecting cellular and humoral immunity.